The National Institute for Health and Care Excellence (NICE) uses the Highly Specialised Technologies (HST) programme to assess medicines and other interventions intended for ultra-rare and debilitating conditions. The programme is reserved for situations where the clinical and economic evaluation of a technology poses particular challenges due to the small patient population, the lack of treatment options, and the difficulty of conducting conventional trials.
